The ongoing Phase 1 trial sponsored by University College London is evaluating a novel BCMA CAR T-cell therapy, both as a standalone treatment and in combination with a CD19 CAR, for patients with relapsed/refractory multiple myeloma. The market for multiple myeloma therapies is expanding, with increasing demand for innovative treatments due to the limitations of existing therapies. The dual-targeting approach may provide a competitive edge in efficacy and safety, addressing a significant unmet need in this patient population. The trial's success could position the sponsor favorably for future partnerships or commercialization opportunities, particularly in the context of advanced therapy medicinal products (ATMPs).